Psilocybin

Safety Summary

Regulatory Status

Sources

These citations are the ones recorded for the human adult context.

• US DEA: Psilocybin and Psilocin — Schedule I Classification, FDA Breakthrough Therapy Designations (Depression), Oregon and Colorado Regulatory Frameworks, Australia Therapeutic Authorization (2023), and Mushroom Misidentification with Galerina (2023) REGULATORY · 2023
• Carhart-Harris R, Goodwin GM: The Therapeutic Potential of Psychedelic Drugs — Psilocybin 5-HT2A Mechanism, Clinical Trial Efficacy Data (TRD and MDD), Physiological Safety Profile, Risk-Benefit at Therapeutic Doses, and Adolescent Brain Development Considerations (Neuropsychopharmacology, 2017; updated 2023) ACADEMIC · 2023
• OEHHA Proposition 65 List of Carcinogens or Reproductive Toxicants (CSV, list date 31-Jul-26) REGULATORY
• Permissible Exposure Limits – OSHA Annotated Table Z-1 REGULATORY
• EPA CompTox CTX API: predicted properties for DTXSID0048898 (Psilocybin) REFERENCE

Same data as the API response, which is open and needs no key. The full per-record source list is available to authenticated callers.